Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.

Eriksson, P; Brattström, D; Hesselius, P; Larsson, A; Bergström, S; Ekman, S; Goike, H; Wagenius, G; Brodin, O; Bergqvist, M

Eriksson, P; Brattström, D; Hesselius, P; Larsson, A; Bergström, S; Ekman, S; Goike, H; Wagenius, G; Brodin, O; Bergqvist, M.

Affiliation

Eriksson P; Department of Oncology, Uppsala University Hospital, 5185 Uppsala, Sweden.

Neoplasma ; 53(4): 285-90, 2006.

Article in En | MEDLINE | ID: mdl-16830054

Subject(s)

Biomarkers, Tumor/blood; Carcinoma, Non-Small-Cell Lung/diagnosis; Fibroblast Growth Factor 2/blood; Keratins/blood; Lung Neoplasms/diagnosis; Vascular Endothelial Growth Factor A/blood; Carcinoma, Non-Small-Cell Lung/therapy; Female; Humans; Immunohistochemistry/methods; Lung Neoplasms/therapy; Male; Risk; Survival Analysis

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Fibroblast Growth Factor 2 / Carcinoma, Non-Small-Cell Lung / Vascular Endothelial Growth Factor A / Keratins / Lung Neoplasms Type of study: Etiology_studies / Evaluation_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Neoplasma Year: 2006 Document type: Article Affiliation country: Sweden

Search on Google

Add to My VHL

XML

PubMed Links